NY-GARIA
5.10.2021 16:55:09 CEST | Business Wire | Press release
Viridi Parente, Inc., a developer of innovative battery technology that can be safely installed and operated in nearly any environment or location, is partnering with Garia Utility , the Denmark-based leader in low-speed utility vehicles , to develop last-mile , low-speed electric utility vehicles for the U.S. market. These vehicles will be manufactured in Buffalo, New York, and branded under the Green Machine Equipment name.
An image of the Green Machine electric, low-speed utility vehicle may be downloaded here - https://rb.gy/uywc9e .
"If we are going to have any impact on decarbonization, we need to rethink our supply chain strategies and equipment options, especially for last-mile delivery," said Jon M. Williams, CEO of Viridi Parente. "Green Machine couldn't ask for a better partner to introduce clean utility vehicles into the U.S. than Garia. Its proven technology is already deployed throughout Europe, and the compact design is ideally suited for use in dense, urban areas in the U.S."
Garia chose to partner with Green Machine because of its proprietary, durable, and safe battery technology that is being used by leading construction brands such as Bobcat and Case . Green Machine was the first manufacturer to introduce all-electric heavy construction and industrial equipment into the market and has perfected the technology with more than 250,000 hours of robust field testing.
Garia Utility has over 900 last-mile vehicles deployed on delivery routes in Sweden through a contract with PostNord (the Swedish Postal Service). The combination of Green Machine's propriety technology and Garia's know-how in the last-mile vehicle space creates a superb clean vehicle that replaces standard diesel or gasoline-powered utility vehicles . For U.S. markets, Green Machine battery technology will increase the range and adaptability of the vehicle.
"After evaluating many potential partners, Viridi Parente was the obvious choice," said Jakob Holstein, CEO of Garia. "Not only did they have the best technology for our needs, but their technology had the most field experience. We were also aligned well on leadership and values."
Green Machine's electric utility vehicles are unlike anything currently available in the U.S. The compact design allows users to access narrow spaces such as constricted roadways, tight alleys, or compressed park or campus pathways. In addition to the traditional model, Green Machine has installed its technology into a right-hand-drive chassis from Garia that squarely fits any delivery needs.
Still dominated by fossil-fuel-powered trucks and vehicles, the supply chain remains a significant source of greenhouse gasses. In New York, transportation accounts for about 36% of the state's carbon emissions. While the nation's reliance on an efficient, reliable supply chain increases, so does the desire to transition long-haul and last-mile delivery to zero-emission vehicle options. McKinsey forecasts that the number of electric utility vehicles will grow from just 5,000 in 2018 to more than 8 million by 2030.
About Viridi Parente
Viridi Parente (Viridi) is a disruptive energy company in Buffalo, New York, that is changing the way we use energy, improving systems, communities, and lives. Viridi deploys safe battery technology into applications that have been historically dominated by fossil fuel energy sources. Its innovative architecture is constructed from materials used for aerospace and military applications and is the only design in the market that can be safely installed and operated in nearly any environment or location. Through its subsidiary, Green Machine Equipment, Viridi is bringing quiet, fully renewable mobile energy solutions to products in construction equipment, waste disposal, last-mile delivery, and other portable industrial markets. Through its subsidiary, Volta Energy Products, Viridi brings stationary, point-of-use storage technology that is safe, locatable, and reliable to industrial, medical, commercial, municipal, and residential building applications. Learn more at: www.viridiparente.com .
About Garia A/S
Garia is a manufacturer of utility vehicles, premium golf, and leisure cars. Founded in 2005 by Anders Lynge, Garia is privately held by Lars Larsen Group and headquartered in Denmark with a subsidiary in the U.S.
In 2015, with ten years of experience in the luxury electric vehicle market, Garia embarked on an entirely new journey: the Garia Utility. A compact electric utility vehicle that combines reliability, ergonomics, and zero emissions with comfort, functionality, and thoughtful design. Made of high-quality European components, the Garia Utility is one of a kind.
Learn more about the Garia Utility at gariautility.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005881/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom